Since its inception in February 2015, Janssen R&D LLC's Disease Interception Accelerator (DIA) – a research initiative focused on prediction and preemption of disease – has signed 24 agreements. The firm highlighted the anniversary March 22 with the unveiling of two new ones to identify disease pathways associated with chronic obstructive pulmonary disease and to identify biomarkers in gestational diabetes mellitus.
These latest agreements build on an initial arrangement with Washington University, unveiled last June, to identify the root causes of type 1 diabetes in hopes of developing interventional methods to halt disease progression ([A#14150612004])
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?